Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Transplantation Conditioning | 34 | 2022 | 1598 | 2.130 |
Why?
|
Graft vs Host Disease | 31 | 2024 | 3042 | 1.910 |
Why?
|
Bone Marrow Transplantation | 29 | 2024 | 2702 | 1.900 |
Why?
|
Hematopoietic Stem Cell Transplantation | 41 | 2024 | 5709 | 1.790 |
Why?
|
Cyclophosphamide | 22 | 2023 | 2224 | 1.740 |
Why?
|
Hematologic Neoplasms | 20 | 2019 | 1905 | 1.250 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 9 | 2017 | 263 | 1.090 |
Why?
|
Bone Neoplasms | 9 | 2022 | 2562 | 1.080 |
Why?
|
Chondrosarcoma | 4 | 2021 | 306 | 1.010 |
Why?
|
Tissue Donors | 13 | 2024 | 2377 | 1.010 |
Why?
|
Osteoblastoma | 2 | 2021 | 24 | 0.940 |
Why?
|
Osteoma, Osteoid | 2 | 2021 | 90 | 0.880 |
Why?
|
HLA Antigens | 12 | 2021 | 1338 | 0.660 |
Why?
|
Hematologic Diseases | 3 | 2023 | 499 | 0.630 |
Why?
|
Busulfan | 9 | 2021 | 259 | 0.630 |
Why?
|
Hematopoietic Stem Cell Mobilization | 7 | 2017 | 225 | 0.600 |
Why?
|
Antigens, CD34 | 5 | 2017 | 656 | 0.590 |
Why?
|
Soft Tissue Neoplasms | 3 | 2021 | 1166 | 0.540 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2023 | 305 | 0.520 |
Why?
|
Immunosuppressive Agents | 13 | 2017 | 4213 | 0.520 |
Why?
|
Hospitals, Special | 1 | 2015 | 90 | 0.500 |
Why?
|
Haplotypes | 6 | 2017 | 2725 | 0.460 |
Why?
|
Transplantation, Homologous | 24 | 2020 | 4834 | 0.440 |
Why?
|
Antilymphocyte Serum | 3 | 2021 | 491 | 0.430 |
Why?
|
Vidarabine | 8 | 2021 | 337 | 0.410 |
Why?
|
Histocompatibility Testing | 9 | 2017 | 716 | 0.370 |
Why?
|
Lymphocyte Depletion | 4 | 2012 | 605 | 0.360 |
Why?
|
Lipoma | 1 | 2012 | 296 | 0.350 |
Why?
|
Chondroma | 2 | 2021 | 53 | 0.350 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 369 | 0.340 |
Why?
|
Liposarcoma | 1 | 2012 | 289 | 0.340 |
Why?
|
Fever | 2 | 2014 | 1622 | 0.340 |
Why?
|
Vidarabine Phosphate | 4 | 2014 | 11 | 0.330 |
Why?
|
Fetal Blood | 4 | 2023 | 1353 | 0.320 |
Why?
|
Myeloablative Agonists | 6 | 2016 | 210 | 0.320 |
Why?
|
Achilles Tendon | 2 | 2024 | 181 | 0.320 |
Why?
|
Bone Marrow | 7 | 2024 | 2929 | 0.310 |
Why?
|
Tendinopathy | 2 | 2024 | 176 | 0.310 |
Why?
|
Guideline Adherence | 2 | 2015 | 2239 | 0.310 |
Why?
|
Tissue and Organ Harvesting | 4 | 2020 | 374 | 0.310 |
Why?
|
Histocompatibility | 4 | 2016 | 322 | 0.300 |
Why?
|
Blood Component Removal | 2 | 2012 | 132 | 0.260 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2024 | 507 | 0.260 |
Why?
|
Donor Selection | 4 | 2019 | 240 | 0.250 |
Why?
|
Granulocyte Colony-Stimulating Factor | 5 | 2016 | 631 | 0.250 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2021 | 3623 | 0.240 |
Why?
|
Adult | 62 | 2024 | 223542 | 0.230 |
Why?
|
Adolescent | 40 | 2022 | 89168 | 0.210 |
Why?
|
Transplantation, Autologous | 5 | 2024 | 2126 | 0.210 |
Why?
|
Health Care Surveys | 1 | 2010 | 2437 | 0.210 |
Why?
|
Arthroplasty, Replacement, Ankle | 1 | 2022 | 26 | 0.200 |
Why?
|
Humans | 98 | 2024 | 768451 | 0.200 |
Why?
|
Middle Aged | 58 | 2024 | 223418 | 0.200 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1139 | 0.190 |
Why?
|
Young Adult | 29 | 2021 | 60045 | 0.190 |
Why?
|
T-Lymphocytes | 6 | 2017 | 10273 | 0.190 |
Why?
|
Enchondromatosis | 1 | 2021 | 14 | 0.190 |
Why?
|
Aged | 44 | 2024 | 171520 | 0.180 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 2001 | 142 | 0.180 |
Why?
|
N-Methylaspartate | 1 | 2001 | 231 | 0.180 |
Why?
|
Male | 67 | 2024 | 364781 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
Transplantation Chimera | 4 | 2015 | 594 | 0.170 |
Why?
|
Erythroid Precursor Cells | 1 | 2001 | 212 | 0.170 |
Why?
|
Chondromatosis, Synovial | 1 | 2019 | 17 | 0.170 |
Why?
|
Receptors, Dopamine D1 | 1 | 2001 | 292 | 0.170 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1505 | 0.160 |
Why?
|
Pruritus | 1 | 2022 | 380 | 0.160 |
Why?
|
Disease-Free Survival | 11 | 2016 | 6856 | 0.160 |
Why?
|
Activin Receptors, Type II | 1 | 2019 | 123 | 0.160 |
Why?
|
Female | 63 | 2024 | 396943 | 0.160 |
Why?
|
Pyramidal Cells | 1 | 2001 | 367 | 0.160 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 303 | 0.150 |
Why?
|
Haploidy | 2 | 2016 | 127 | 0.140 |
Why?
|
Killer Cells, Natural | 2 | 2017 | 2209 | 0.140 |
Why?
|
Child | 24 | 2022 | 80863 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2019 | 583 | 0.140 |
Why?
|
Hematopoietic Stem Cells | 3 | 2017 | 3408 | 0.140 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2017 | 119 | 0.130 |
Why?
|
Hodgkin Disease | 3 | 2011 | 1386 | 0.130 |
Why?
|
Fibronectins | 1 | 2019 | 725 | 0.130 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 93 | 0.130 |
Why?
|
Living Donors | 2 | 2010 | 651 | 0.120 |
Why?
|
Retrospective Studies | 20 | 2022 | 81834 | 0.120 |
Why?
|
Biopsy, Needle | 1 | 2020 | 1629 | 0.120 |
Why?
|
Whole-Body Irradiation | 4 | 2021 | 434 | 0.120 |
Why?
|
Cell Separation | 1 | 2001 | 1726 | 0.120 |
Why?
|
Erdheim-Chester Disease | 1 | 2014 | 10 | 0.120 |
Why?
|
Osteoarthritis | 1 | 2022 | 1070 | 0.120 |
Why?
|
Dyspnea | 1 | 2022 | 1352 | 0.120 |
Why?
|
Biomarkers, Pharmacological | 2 | 2013 | 162 | 0.110 |
Why?
|
Melphalan | 1 | 2015 | 420 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1320 | 0.110 |
Why?
|
Lymphopoiesis | 1 | 2014 | 133 | 0.110 |
Why?
|
Isoantibodies | 1 | 2018 | 682 | 0.110 |
Why?
|
Treatment Outcome | 20 | 2024 | 65409 | 0.110 |
Why?
|
Recurrence | 10 | 2014 | 8510 | 0.110 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 928 | 0.110 |
Why?
|
Graft Survival | 5 | 2015 | 3890 | 0.110 |
Why?
|
Mesenchymal Stem Cells | 1 | 2024 | 1671 | 0.110 |
Why?
|
Area Under Curve | 3 | 2013 | 1640 | 0.110 |
Why?
|
Bacteremia | 1 | 2020 | 985 | 0.110 |
Why?
|
Filgrastim | 4 | 2015 | 132 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2568 | 0.100 |
Why?
|
Survival Rate | 8 | 2017 | 12875 | 0.100 |
Why?
|
Lymphoma | 1 | 2022 | 1907 | 0.100 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1244 | 0.100 |
Why?
|
Foot Diseases | 1 | 2013 | 148 | 0.100 |
Why?
|
Accreditation | 1 | 2015 | 478 | 0.100 |
Why?
|
Pilot Projects | 5 | 2024 | 8730 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2001 | 1228 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 2525 | 0.090 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2415 | 0.090 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 525 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 11843 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9425 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 618 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 647 | 0.090 |
Why?
|
Synovitis, Pigmented Villonodular | 1 | 2010 | 32 | 0.090 |
Why?
|
Blood Donors | 1 | 2012 | 345 | 0.090 |
Why?
|
Prefrontal Cortex | 1 | 2001 | 2251 | 0.090 |
Why?
|
Acute Disease | 6 | 2024 | 7246 | 0.090 |
Why?
|
Pain | 5 | 2022 | 5096 | 0.090 |
Why?
|
Graft Rejection | 5 | 2018 | 4505 | 0.080 |
Why?
|
Osteitis | 1 | 2009 | 33 | 0.080 |
Why?
|
Fanconi Anemia | 1 | 2012 | 327 | 0.080 |
Why?
|
Salvage Therapy | 1 | 2016 | 1277 | 0.080 |
Why?
|
Foot | 1 | 2013 | 577 | 0.080 |
Why?
|
Sarcoma | 1 | 2020 | 1806 | 0.080 |
Why?
|
Incidence | 9 | 2023 | 21552 | 0.080 |
Why?
|
Lymphocyte Transfusion | 2 | 2016 | 232 | 0.080 |
Why?
|
Physician Executives | 1 | 2010 | 137 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2011 | 1376 | 0.080 |
Why?
|
Hospital Bed Capacity | 1 | 2010 | 206 | 0.080 |
Why?
|
Leukemia, Myeloid | 3 | 2014 | 693 | 0.080 |
Why?
|
Mixed Tumor, Malignant | 1 | 2008 | 16 | 0.080 |
Why?
|
Myoepithelioma | 1 | 2008 | 26 | 0.080 |
Why?
|
Liposarcoma, Myxoid | 1 | 2008 | 60 | 0.070 |
Why?
|
Blood Specimen Collection | 1 | 2009 | 238 | 0.070 |
Why?
|
Immunoconjugates | 1 | 2015 | 968 | 0.070 |
Why?
|
Fetal Proteins | 1 | 2008 | 99 | 0.070 |
Why?
|
Gene Amplification | 1 | 2012 | 1091 | 0.070 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2007 | 42 | 0.070 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2008 | 96 | 0.070 |
Why?
|
Follow-Up Studies | 7 | 2020 | 39430 | 0.070 |
Why?
|
Models, Biological | 3 | 2014 | 9505 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1602 | 0.070 |
Why?
|
Muscle Neoplasms | 1 | 2008 | 130 | 0.070 |
Why?
|
Histones | 1 | 2017 | 2595 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2489 | 0.070 |
Why?
|
Child, Preschool | 10 | 2022 | 42623 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 2000 | 0.070 |
Why?
|
Joint Diseases | 1 | 2010 | 460 | 0.070 |
Why?
|
Chronic Disease | 6 | 2023 | 9382 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 7 | 2022 | 36840 | 0.060 |
Why?
|
Muscle, Skeletal | 2 | 2013 | 4984 | 0.060 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 306 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2012 | 8559 | 0.060 |
Why?
|
T-Box Domain Proteins | 1 | 2008 | 473 | 0.060 |
Why?
|
Fatigue | 1 | 2012 | 1556 | 0.060 |
Why?
|
Bone Marrow Purging | 2 | 2002 | 108 | 0.060 |
Why?
|
Hemangioma | 1 | 2010 | 727 | 0.060 |
Why?
|
Myelodysplastic Syndromes | 3 | 2016 | 1400 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 556 | 0.060 |
Why?
|
Chordoma | 1 | 2008 | 350 | 0.060 |
Why?
|
Adoptive Transfer | 1 | 2007 | 825 | 0.060 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 895 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4285 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2012 | 2326 | 0.050 |
Why?
|
Informed Consent | 1 | 2010 | 1012 | 0.050 |
Why?
|
Remission Induction | 4 | 2013 | 2408 | 0.050 |
Why?
|
Blood Cell Count | 2 | 2015 | 402 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 3108 | 0.050 |
Why?
|
Cell Count | 2 | 2019 | 1835 | 0.050 |
Why?
|
Family | 2 | 2011 | 3208 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2021 | 59680 | 0.050 |
Why?
|
Hypoglycemia | 1 | 2009 | 894 | 0.050 |
Why?
|
United States | 5 | 2023 | 73121 | 0.050 |
Why?
|
Knee Joint | 1 | 2010 | 1683 | 0.050 |
Why?
|
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2001 | 54 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2017 | 1014 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6537 | 0.050 |
Why?
|
State Medicine | 1 | 2022 | 217 | 0.050 |
Why?
|
Arthrodesis | 1 | 2022 | 186 | 0.050 |
Why?
|
Hematopoiesis | 2 | 2021 | 2058 | 0.050 |
Why?
|
Fluorometry | 1 | 2001 | 99 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2022 | 13026 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12561 | 0.050 |
Why?
|
Mutation | 4 | 2020 | 30243 | 0.040 |
Why?
|
Nuclear Family | 1 | 2002 | 311 | 0.040 |
Why?
|
Chimerism | 1 | 2021 | 156 | 0.040 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 945 | 0.040 |
Why?
|
Hyperglycemia | 1 | 2009 | 1389 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2007 | 1894 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20762 | 0.040 |
Why?
|
Ankle | 1 | 2022 | 354 | 0.040 |
Why?
|
Oncogene Fusion | 1 | 2019 | 83 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3207 | 0.040 |
Why?
|
Switzerland | 1 | 2019 | 322 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 437 | 0.040 |
Why?
|
Mycophenolic Acid | 2 | 2013 | 350 | 0.040 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2001 | 484 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 4419 | 0.040 |
Why?
|
Injections, Intravenous | 2 | 2011 | 1379 | 0.040 |
Why?
|
Patch-Clamp Techniques | 1 | 2001 | 927 | 0.040 |
Why?
|
Ankle Joint | 1 | 2022 | 447 | 0.040 |
Why?
|
Dopamine Agonists | 1 | 2001 | 353 | 0.040 |
Why?
|
England | 1 | 2019 | 533 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1154 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 313 | 0.040 |
Why?
|
Electrophysiology | 1 | 2001 | 1266 | 0.040 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6527 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 259 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 213 | 0.040 |
Why?
|
London | 1 | 2018 | 233 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 462 | 0.040 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11138 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4642 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2019 | 15880 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2014 | 7895 | 0.040 |
Why?
|
Calcium Channels | 1 | 2001 | 624 | 0.040 |
Why?
|
Antineoplastic Agents | 4 | 2012 | 13708 | 0.030 |
Why?
|
Animals | 4 | 2022 | 169418 | 0.030 |
Why?
|
Receptors, KIR | 1 | 2016 | 114 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2023 | 5532 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 984 | 0.030 |
Why?
|
Risk Factors | 7 | 2024 | 74915 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2020 | 13589 | 0.030 |
Why?
|
Cyclosporine | 1 | 1998 | 780 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 257 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40271 | 0.030 |
Why?
|
Survival Analysis | 4 | 2014 | 10125 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 307 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 637 | 0.030 |
Why?
|
Extremities | 1 | 2020 | 870 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4861 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 640 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2001 | 1308 | 0.030 |
Why?
|
Cause of Death | 2 | 2021 | 3727 | 0.030 |
Why?
|
Spine | 1 | 2021 | 1142 | 0.030 |
Why?
|
Bayes Theorem | 2 | 2014 | 2358 | 0.030 |
Why?
|
Heel | 1 | 2013 | 38 | 0.030 |
Why?
|
Half-Life | 1 | 2014 | 650 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 681 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1669 | 0.030 |
Why?
|
Anesthesia | 2 | 2015 | 1596 | 0.030 |
Why?
|
Disease Progression | 3 | 2017 | 13655 | 0.030 |
Why?
|
Convalescence | 1 | 2012 | 109 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2014 | 793 | 0.030 |
Why?
|
Decision Trees | 1 | 2014 | 510 | 0.020 |
Why?
|
Prospective Studies | 4 | 2019 | 54914 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2611 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2015 | 1615 | 0.020 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2017 | 954 | 0.020 |
Why?
|
Bone and Bones | 1 | 2021 | 2589 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9263 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 2024 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2015 | 1869 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2012 | 538 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2001 | 5904 | 0.020 |
Why?
|
Siblings | 1 | 2014 | 829 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2011 | 699 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2001 | 8201 | 0.020 |
Why?
|
Syncope | 1 | 2012 | 430 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15460 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 3050 | 0.020 |
Why?
|
Europe | 1 | 2015 | 3439 | 0.020 |
Why?
|
Glutathione Transferase | 1 | 2010 | 567 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7605 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2015 | 839 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 712 | 0.020 |
Why?
|
Prognosis | 4 | 2017 | 30028 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2014 | 614 | 0.020 |
Why?
|
Spermatogonia | 1 | 2008 | 30 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 6091 | 0.020 |
Why?
|
International Cooperation | 1 | 2014 | 1439 | 0.020 |
Why?
|
Exanthema | 1 | 2012 | 504 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20231 | 0.020 |
Why?
|
Hemangioblastoma | 1 | 2008 | 62 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1855 | 0.020 |
Why?
|
Quality of Life | 2 | 2023 | 13497 | 0.020 |
Why?
|
Blood Component Transfusion | 1 | 2008 | 142 | 0.020 |
Why?
|
Leukemia | 1 | 2015 | 1527 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2010 | 496 | 0.020 |
Why?
|
Infant | 3 | 2010 | 36497 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 13030 | 0.020 |
Why?
|
Synovial Membrane | 1 | 2010 | 536 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4342 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15965 | 0.020 |
Why?
|
Leukapheresis | 1 | 2007 | 150 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4630 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2575 | 0.020 |
Why?
|
Neoplasms | 2 | 2014 | 22386 | 0.020 |
Why?
|
Income | 1 | 2015 | 1878 | 0.020 |
Why?
|
Algorithms | 2 | 2011 | 14158 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5308 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11249 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2003 | 5192 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2010 | 2228 | 0.020 |
Why?
|
Rats | 1 | 2001 | 23839 | 0.010 |
Why?
|
Diphosphonates | 1 | 2009 | 635 | 0.010 |
Why?
|
Medicare | 1 | 2023 | 6881 | 0.010 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2007 | 238 | 0.010 |
Why?
|
Tacrolimus | 1 | 2008 | 750 | 0.010 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 998 | 0.010 |
Why?
|
Virus Activation | 1 | 2006 | 322 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1207 | 0.010 |
Why?
|
Immunotherapy | 1 | 2000 | 4728 | 0.010 |
Why?
|
Receptors, IgG | 1 | 2007 | 564 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2010 | 964 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9642 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2010 | 941 | 0.010 |
Why?
|
Sex Factors | 1 | 2017 | 10647 | 0.010 |
Why?
|
Cohort Studies | 3 | 2014 | 41797 | 0.010 |
Why?
|
Proteomics | 1 | 2017 | 3901 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2010 | 12096 | 0.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 495 | 0.010 |
Why?
|
Administration, Oral | 1 | 2010 | 4041 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1744 | 0.010 |
Why?
|
Lung | 1 | 2020 | 10090 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 2008 | 806 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1481 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7471 | 0.010 |
Why?
|
Baltimore | 1 | 2001 | 234 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2391 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2008 | 2204 | 0.010 |
Why?
|
Health Care Costs | 1 | 2014 | 3265 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2006 | 1081 | 0.010 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2006 | 616 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2279 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2002 | 1604 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10358 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 695 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4029 | 0.010 |
Why?
|
Computer Simulation | 1 | 2010 | 6278 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18388 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 13047 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6320 | 0.010 |
Why?
|
Blood Glucose | 1 | 2009 | 6429 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 11930 | 0.010 |
Why?
|
Hospitalization | 1 | 2012 | 10845 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2008 | 6657 | 0.010 |
Why?
|
Comorbidity | 1 | 2006 | 10601 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 13065 | 0.010 |
Why?
|
Phenotype | 1 | 2008 | 16712 | 0.010 |
Why?
|
Neutrophils | 1 | 2002 | 3790 | 0.010 |
Why?
|
Mice | 1 | 2015 | 82045 | 0.000 |
Why?
|
Age Factors | 1 | 2003 | 18478 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2001 | 14766 | 0.000 |
Why?
|